PRMT5 and urinary bladder carcinoma: Similarly, PRMT5 inhibitor EPZ015666 significantly inhibited NF-κB activation and its target gene trasncription in T24 bladder cancer cells (Figure 4C & 4D(Fig. 4), right panels).